Published on 3 Jul 2023 on Zacks via Yahoo Finance
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
Baudax Bio BXRX acquired TeraImmune, a privately held company that’s focused on the discovery and development of Treg-based cell therapies for autoimmune diseases. Shares of Baudax Bio soared almost 125% on Jun 30, following the news.
The acquisition will add TeraImmune's TI-168 asset to Baudax Bio's portfolio. TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to eliminate clotting factor VIII (FVIII) inhibitors in patients with hemophilia A.
An investigational new drug application for TI-168 has been recently approved by the FDA. Baudax Bio believes that with a modest initial budget, it can initiate the phase I/IIa clinical study of TI-168 for the treatment of hemophilia A.